about
Adjuvanted influenza a (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy-treated patients.G- and GM-CSF in oncology and oncological haematology.Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.Utility of bronchoalveolar lavage in diagnosing respiratory tract infections in patients with hematological malignancies: are invasive diagnostics still needed?Epidemiology of chronic myeloid leukaemia: an update.The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses.HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia.Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden.Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)--what is the difference?Successful treatment of chronic wound infection in neutropenia and rheumatoid arthritis with filgrastim (rhG-GSF)Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia.Effects of in vivo administration of G-CSF on neutrophil and eosinophil adhesion.Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemiaTopoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.Answer to "Letter to the Editor, Scandinavian Journal of Infectious Diseases".Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients.Complete molecular remission in chronic myelogenous leukemia after imatinib therapy.Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia.Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.Cryoglobulins induce temperature-dependent TNF-α production via Fcγ-receptor II.Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013.Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.Reply to D. Pulte et al.Treatment of pure red-cell aplasia and aplastic anaemia with ciclosporin: long-term clinical effects.Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patientsThe effect of granulocyte colony-stimulating factor (G-CSF) on the degranulation of secondary granule proteins from human neutrophils in vivo may be indirectDose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF[Malignant lymphoma. Experiences with autologous bone marrow transplantation in 50 patients]The effect of rGM-CSF on neutrophil and eosinophil regeneration after ABMT as monitored by circulating levels of granule proteinsAdministration of G-CSF to healthy subjects: the effects on eosinophil counts and mobilization of eosinophil granule proteinsEffects of in vivo administration of G-CSF on neutrophil functions in healthy volunteers
P50
Q30427666-CB6FDBE8-94B7-4FC0-984A-24A8AFA7AE3DQ33487910-45F1FAB7-4DFC-4E97-8CD5-C245E7582BF5Q33646189-24213300-B7C6-4EDF-849E-BD105EC938D7Q35194464-962338F0-5B67-47D4-98E8-DBC5575968E6Q35753087-6B43672A-DA15-416C-9C62-7B202BEA962EQ37715218-1B68B2BC-E388-457F-B43A-6E5D8129873DQ38392709-24C23DE9-A812-4582-8029-64A59B7C9C43Q38415063-FCCE8408-E4F1-4542-A8F4-86CD749C1ABFQ38753227-509984B0-9341-42D2-B524-28E01BDEC6C1Q38850383-8F88EF2B-FBD2-4FF5-B625-14B50E7F6CC9Q39066180-0D16F4A3-D5F2-460B-B0D6-90771529EBE1Q39446340-17C38E61-D73F-47D8-A07D-4F2F5F1175DCQ39591396-E69F0E47-EFC8-4158-9988-D64A4F42B04DQ40219685-BD3981F2-3C48-4A4F-AD80-E37F87DF0384Q40799115-D9C150BA-8002-4C52-8CE4-9CA0A9B480B8Q40974493-9C1FF7F5-29E0-40DB-A57F-0C4B710FE6E7Q41934820-E496822F-600B-4766-A868-ACD113898A63Q42274119-09342E73-EA87-441B-AE03-695D4F3B8BC0Q42445533-0EDCBF00-B971-49C1-B450-023786735563Q42538832-8484B51D-B2D1-41E6-B756-2BFD2549528CQ43249784-CF30A363-258C-4E90-8C7F-B6CA3819AB42Q43597348-D3A4A87F-598D-4B8D-AF7D-52367849A251Q43627853-B75777E5-D9C5-4E16-9BBF-7503456EA0A8Q44104232-1E09B4C1-C5A6-46BF-BD71-E5D0FA844B5BQ45848278-D1396C60-387A-4719-A84C-7B4E789C3432Q46040796-C55001E3-B2DF-43A1-AD57-BDF5FE74FA6BQ46510440-F8E1D65F-0196-4596-9EFC-4EFBB1CEAC85Q48200551-7DB50A2F-37DA-41FE-945E-ABF8B61C3277Q51474049-5574B60E-9332-4EEF-8EFB-8776A770F399Q53026370-8126D548-3310-4204-B5B8-C45E585B5DC9Q53971594-47CAEF40-A2C5-4045-9B4D-C2C33CBF5372Q54361476-7AA3A36F-A79C-4031-A775-DCA5CCA5CE6EQ55062685-CD00CE68-522A-4047-A3E4-610D0AB0E09BQ61776674-2A30572C-C0BF-43D0-B6D3-99EFD79826A7Q71127528-7A982316-064E-4507-B5D8-B72BAB1F4059Q71592571-9B6E497C-D5CD-4889-A9EA-DBD5DF028C3AQ72583257-1CA9ECA0-9119-4C30-AAF9-2D71A4F6562FQ72695697-3BC25AD6-23FB-43D5-AAA2-8A0FA69A7643Q73064099-6E30C263-109F-4A25-87AD-19A763F30893Q73338527-1B32DCB8-78D0-49BD-B242-8919E9BAAF05
P50
description
Zweeds onderzoeker
@nl
forsker
@nb
researcher
@en
հետազոտող
@hy
name
M. Hoglund
@ast
M. Hoglund
@es
M. Hoglund
@nl
M. Hoglund
@sl
Martin Hoglund
@en
Martin Hoglund
@nb
type
label
M. Hoglund
@ast
M. Hoglund
@es
M. Hoglund
@nl
M. Hoglund
@sl
Martin Hoglund
@en
Martin Hoglund
@nb
altLabel
M. Hoglund
@en
prefLabel
M. Hoglund
@ast
M. Hoglund
@es
M. Hoglund
@nl
M. Hoglund
@sl
Martin Hoglund
@en
Martin Hoglund
@nb
P108
P106
P27
P31
P496
0000-0003-2468-0226